We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Roche (RHHBY) Hemophilia A Drug Granted Priority Review
Read MoreHide Full Article
Roche Holding AG (RHHBY - Free Report) announced that the FDA has accepted the company’s Biologics License Application (BLA) and granted Priority Review for hemophilia A candidate, emicizumab.
The FDA has granted emicizumab prophylaxis (preventative) priority review as a once-weekly subcutaneous treatment for adults, adolescents and children with hemophilia A with factor VIII inhibitors.
Priority Review designation from the FDA is generally granted to drugs that have the potential to provide significant improvements in the safety and effectiveness of the treatment, prevention or diagnosis of a serious disease.
The BLA for emicizumab was based on results from the phase III study, HAVEN 1, in adults and adolescents of 12 years or older, as well as interim results from the phase III study, HAVEN 2 study in children younger than 12 years of age.
We note that results from HAVEN 1 were published in The New England Journal of Medicine (NEJM) and results from both studies were presented at the 26th International Society on Thrombosis and Haemostasis (ISTH) Congress in July 2017.
The FDA is expected to give a decision by Feb 23, 2018. We remind investors that the FDA granted Breakthrough Therapy Designation for emicizumab in adults and adolescents with haemophilia A with inhibitors in September 2015.
Meanwhile, Roche is evaluating emicizumab in patients with hemophilia A both with and without inhibitors and evaluating less frequent dosing regimens as well.
Roche’s stock has lost 10.1% so far in 2017 against the industry’s 10.3% gain.
Along with emicizumab, Roche’s hematology portfolio at present consists of MabThera/Rituxan, Gazyva/Gazyvaro and VenclextaTM/VenclyxtoTM in collaboration with AbbVie, Inc (ABBV - Free Report) along with a pipeline which has a small molecule antagonist of MDM2 (idasanutlin/RG7388) and polatuzumab vedotin.
A few other companies are also developing treatments for hemophilia A. Shire plc also filed an investigational new drug (IND) application with the FDA, seeking approval for recombinant factor VIII (FVIII) gene therapy candidate, SHP654. The drug will be used for the treatment of patients with hemophilia A.
Gilead’s earnings per share estimates increased from $7.98 to $8.53 for 2017, over the last 30 days. The company delivered positive earnings surprises in three of the trailing four quarters, with an average beat of 8.18%.
One Simple Trading Idea
Since 1988, the Zacks system has more than doubled the S&P 500 with an average gain of +25% per year. With compounding, rebalancing, and exclusive of fees, it can turn thousands into millions of dollars.
This proven stock-picking system is grounded on a single big idea that can be fortune shaping and life changing. You can apply it to your portfolio starting today. Learn more >>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Roche (RHHBY) Hemophilia A Drug Granted Priority Review
Roche Holding AG (RHHBY - Free Report) announced that the FDA has accepted the company’s Biologics License Application (BLA) and granted Priority Review for hemophilia A candidate, emicizumab.
The FDA has granted emicizumab prophylaxis (preventative) priority review as a once-weekly subcutaneous treatment for adults, adolescents and children with hemophilia A with factor VIII inhibitors.
Priority Review designation from the FDA is generally granted to drugs that have the potential to provide significant improvements in the safety and effectiveness of the treatment, prevention or diagnosis of a serious disease.
The BLA for emicizumab was based on results from the phase III study, HAVEN 1, in adults and adolescents of 12 years or older, as well as interim results from the phase III study, HAVEN 2 study in children younger than 12 years of age.
We note that results from HAVEN 1 were published in The New England Journal of Medicine (NEJM) and results from both studies were presented at the 26th International Society on Thrombosis and Haemostasis (ISTH) Congress in July 2017.
The FDA is expected to give a decision by Feb 23, 2018. We remind investors that the FDA granted Breakthrough Therapy Designation for emicizumab in adults and adolescents with haemophilia A with inhibitors in September 2015.
Meanwhile, Roche is evaluating emicizumab in patients with hemophilia A both with and without inhibitors and evaluating less frequent dosing regimens as well.
Roche’s stock has lost 10.1% so far in 2017 against the industry’s 10.3% gain.
Along with emicizumab, Roche’s hematology portfolio at present consists of MabThera/Rituxan, Gazyva/Gazyvaro and VenclextaTM/VenclyxtoTM in collaboration with AbbVie, Inc (ABBV - Free Report) along with a pipeline which has a small molecule antagonist of MDM2 (idasanutlin/RG7388) and polatuzumab vedotin.
A few other companies are also developing treatments for hemophilia A. Shire plc also filed an investigational new drug (IND) application with the FDA, seeking approval for recombinant factor VIII (FVIII) gene therapy candidate, SHP654. The drug will be used for the treatment of patients with hemophilia A.
Zacks Rank and Stock to Consider
Roche currently carries a Zacks Rank #3 (Hold). A better-ranked stock in the health care sector is Gilead Sciences, Inc. (GILD - Free Report) , which carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Gilead’s earnings per share estimates increased from $7.98 to $8.53 for 2017, over the last 30 days. The company delivered positive earnings surprises in three of the trailing four quarters, with an average beat of 8.18%.
One Simple Trading Idea
Since 1988, the Zacks system has more than doubled the S&P 500 with an average gain of +25% per year. With compounding, rebalancing, and exclusive of fees, it can turn thousands into millions of dollars.
This proven stock-picking system is grounded on a single big idea that can be fortune shaping and life changing. You can apply it to your portfolio starting today. Learn more >>